Table 2.
Summary of reports of drug screening with organoid methods.
| Cancer type | Organoid Type | Library | # Compounds Tested | # Cases Tested | Assay Conditions | Reference |
|---|---|---|---|---|---|---|
| Colorectal | CSC-derived | Target-known inhibitors + chemo drugs | 83 | 19 | With 2% BME in culture medium on BME | [76] |
| Breast | CSC-derived | EGFR/AKT/mTORC pathway inhibitors | 6 | 28 | With 2% BME in culture medium on BME | [78] |
| Gastric | CSC-derived | Approved anti-cancer drugs | 37 | 7 | On 50% Matrigel | [77] |
| Bladder | CSC-derived | Target-known inhibitors + chemo drugs | 50 | 11 | With 2% Matrigel in culture medium | [102] |
| Liver | CSC-derived | NCI-Approved Oncology Drugs Set VII | 129 | 5 | In Matrigel | [103] |
| Various | CSC-derived | Chemo drugs and targeted agents under clinical development | 160 (single) + 120 (combination) | 4 | 2D culture of organoids for screening | [104] |
| Ovarian | CSC-derived | Target-known inhibitors + chemo drugs | 22 | 10 | With 2% Matrigel in culture medium on Matrigel | [105] |
| Colorectal | CSC-derived * | Target-known inhibitors + chemo drugs | 8 | 19 | In Matrigel | [106] |
| Endometrial | CTOS | Target-known inhibitors | 79 | 5 (2 hit drugs evaluated in 12 CTOS lines) | w/o matrix | [100] |
| Colorectal | CTOS | Target-known inhibitors | 71 | 1 | w/o matrix | [87] |
| Colorectal | CTOS | Target-known inhibitors + FDA-approved drugs | 2427 | 2 (15 hit drugs evaluated in 30 CTOS lines) | w/o matrix | [42] |
* Prepared by CTOS method. CSC, cancer stem cell; CTOS, cancer tissue-originated spheroid; BME, basement membrane extract.